The presence of anti-phosphatidylserine/prothrombin antibodies as risk factor for both arterial and venous thrombosis in patients with systemic lupus erythematosus

被引：1
|
作者：
Nojima, Junzo [1 ]
Iwatani, Yoshinori [2 ]
Suehisa, Etsuji [1 ]
Kuratsune, Hirohiko [3 ]
Kanakura, Yuzuru [4 ]
机构：
[1] Osaka Univ Hosp, Lab Clin Invest, Suita, Osaka 5650871, Japan
[2] Osaka Univ, Div Biomed Informat, Course Hlth Sci, Grad Sch Med, Suita, Osaka, Japan
[3] Kansai Univ Welf Sci, Fac Hlth Sci Welf, Dept Hlth Sci, Osaka 5820026, Japan
[4] Osaka Univ, Dept Hematol & Oncol, Grad Sch Med, Suita, Osaka, Japan
来源：
HAEMATOLOGICA | 2006年 / 91卷 / 05期
关键词：
anti-phospholipid antibodies; systemic lupus erythematosus; anti-beta 2-glycoprotein I antibodies; anti-phosphatidylserine/prothrombin antibodies;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
In an effort to clarify the clinical significance of anti-phospholipid antibodies (aPL) detected by enzyme-linked immunosorbent assay (ELISA), we examined the prevalence of anti-cardiolipin antibodies (aCL), anti-beta 2-glycoprotein I antibodies (anti-beta 2-GPI), anti-prothrombin antibodies (anti-PT), and anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT) in 175 patients with systemic lupus erythematosus (SLE) comprising 67 patients with thrombotic complications. The present study showed that positive results of anti-beta 2-GPI-ELISA and anti-PS/PT-ELISA could serve as markers of thrombotic complications in patients with SLE, whereas aCL and anti-PT are less reliable as markers of these complications. Furthermore, results of the anti-PS/PT-ELISA correlate best with the occurrence of both arterial and venous thrombosis in patients with SLE.
引用
收藏
页码：699 / 702
页数：4
相关论文
共 50 条
  • [1] The role of anti-phosphatidylserine/prothrombin antibodies in thrombotic manifestations of systemic lupus erythematosus patients
    Tselios, Konstantinos
    Sarantopoulos, Alexandros
    Gkougkourellas, Ioannis
    Boura, Panagiota
    [J]. FRONTIERS IN NEUROLOGY, 2013, 4
  • [2] Antibodies to Phosphatidylserine/Prothrombin (aPS/PT) Are An Independent Risk Factor for Thrombosis in Patients with Systemic Lupus Erythematosus (SLE)
    Bertolaccini, Maria Laura
    Sciascia, Savino
    Murru, Veronica
    Garcia-Fernandez, Cesar
    Sanna, Giovanni
    Khamashta, Munther A.
    [J]. ARTHRITIS AND RHEUMATISM, 2011, 63 (10): : S9 - S10
  • [3] Validation of a commercially available kit to detect anti-phosphatidylserine/prothrombin antibodies in a cohort of systemic lupus erythematosus patients
    Sciascia, Savino
    Sanna, Giovanni
    Murru, Veronica
    Khamashta, Munther A.
    Bertolaccini, Maria Laura
    [J]. THROMBOSIS RESEARCH, 2014, 133 (03) : 451 - 454
  • [4] A Prospective Study on the Incidence of a First Thrombo-embolic Event in Patients with Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies
    Sciascia, Savino
    Radin, Massimo
    Cecchi, Irene
    Rossi, Daniela
    Roccatello, Dario
    [J]. ARTHRITIS & RHEUMATOLOGY, 2020, 72
  • [5] Incidence of a First Thrombo-Embolic Event in Patients With Systemic Lupus Erythematosus and Anti-phosphatidylserine/prothrombin Antibodies: A Prospective Study
    Sciascia, Savino
    Radin, Massimo
    Cecchi, Irene
    Rubini, Elena
    Foddai, Silvia Grazietta
    Barinotti, Alice
    Vaccarino, Antonella
    Rossi, Daniela
    Roccatello, Dario
    [J]. FRONTIERS IN MEDICINE, 2021, 8
  • [6] Anti-phosphatidylserine/prothrombin complex antibodies (aPS/PT) increase the risk for thrombosis based on lupus anticoagulant positivity
    Zhang, Yuncong
    Su, Yang
    Guo, Han
    Wang, Lu
    Li, Aiwei
    Wang, Chanjuan
    Zhang, Jie
    Qiao, Rui
    [J]. CLINICAL BIOCHEMISTRY, 2023, 112 : 17 - 23
  • [7] Anti-prothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome
    Sciascia, Savino
    Sanna, Giovanni
    Murru, Veronica
    Roccatello, Dario
    Khamashta, Munther A.
    Bertolaccini, Maria Laura
    [J]. THROMBOSIS AND HAEMOSTASIS, 2014, 111 (02) : 354 - 364
  • [8] Anti-Phosphatidylserine/Prothrombin Antibodies at Two Points: Correlation With Lupus Anticoagulant and Thrombotic Risk
    Egri, Natalia
    Bentow, Chelsea
    Rubio, Laura
    Norman, Gary L.
    Lopez-Sanudo, Susana
    Mahler, Michael
    Perez-Isidro, Albert
    Cervera, Ricard
    Vinas, Odette
    Espinosa, Gerard
    Ruiz-Ortiz, Estibaliz
    [J]. FRONTIERS IN IMMUNOLOGY, 2021, 12
  • [9] Anti-phosphatidylserine/prothrombin antibodies in patients with polyarteritis nodosa
    Marcela Sanchez-Cubias, Susy
    Martin-Nares, Eduardo
    Hernandez-Molina, Gabriela
    Nunez-Alvarez, Carlos A.
    Antonio Sedano-Montoya, Manuel
    Gabriel Vargas-Ruiz, Angel
    Hinojosa-Azaola, Andrea
    [J]. REUMATOLOGIA CLINICA, 2021, 17 (09): : 521 - 524
  • [10] Lupus anticoagulant is the strongest risk factor for both venous and arterial thrombosis in patients with systemic lupus erythematosus - Comparison between different assays for the detection of antiphospholipid antibodies
    Horbach, DA
    vanOort, E
    Donders, RCJM
    Derksen, RHWM
    deGroot, PG
    [J]. THROMBOSIS AND HAEMOSTASIS, 1996, 76 (06) : 916 - 924
12345